论文部分内容阅读
目的 探讨尿激酶型纤溶酶原激活剂 (uPA)在人脑胶质瘤中的表达特征 ,研究其表达的临床意义。方法 用免疫组化的方法检测uPA在 5 2例胶质瘤、4例垂体腺瘤、5例正常脑组织中的表达情况 ,并结合临床资料分析其表达的意义。结果 5 2例胶质瘤中均有uPA的表达 ,随着其恶性程度的升高 ,其表达也随之升高 ,且分布不均匀。在垂体腺瘤中低度表达 ,在正常脑组织中无表达。高级别胶质瘤中uPA的表达与低级别胶质瘤比较有显著差异性 (P <0 .0 1) ;低级别胶质瘤与垂体腺瘤和正常脑组织中uPA的表达也有显著差异性 (P <0 .0 1)。生存期 <3年者uPA的表达显著高于生存期 >3年者 (P <0 .0 1)。结论 uPA的表达与胶质瘤的侵袭性和血管的生成等有关 ,并对其预后的判断有一定意义。
Objective To investigate the expression of urokinase-type plasminogen activator (uPA) in human glioma and its clinical significance. Methods The expression of uPA in 52 cases of gliomas, 4 cases of pituitary adenomas and 5 cases of normal brain tissues was detected by immunohistochemistry. The significance of uPA expression was analyzed with clinical data. Results The expression of uPA was present in 52 cases of gliomas. With the increase of malignant degree, the expression of uPA also increased and the distribution was uneven. Low expression in pituitary adenomas, no expression in normal brain tissue. The expression of uPA in high-grade gliomas was significantly different from that of low-grade gliomas (P <0.01). The expression of uPA in low-grade gliomas and pituitary adenomas and normal brain tissues was also significantly different (P <0. 01). The expression of uPA in survival time <3 years was significantly higher than that in survival> 3 years (P <0.01). Conclusion The expression of uPA is related to the invasion of glioma and the formation of blood vessels, and it is of certain significance to judge the prognosis.